Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-07-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于股东股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the release of pledged shares by a shareholder. It details the number of shares released from pledge, the shareholder involved, and cumulative pledge status. There is no financial report, earnings data, or management discussion. The document is short (1367 characters) and serves as a notification about share pledge status changes. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about share pledge changes and does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-07-09 Chinese
股东股份减持的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a shareholder's reduction in shareholding. It details the number of shares reduced, the methods of reduction, the periods, prices, and the shareholder's holdings before and after the reduction. It references compliance with relevant regulations on shareholder share reduction and confirms that the reduction aligns with previously disclosed plans. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a shareholder's transaction in their own shares, which fits the category of 'Transaction in Own Shares'. The document length is short and focused solely on shareholding changes, not a report or announcement of a report publication.
2021-07-06 Chinese
关于股东股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company regarding the pledge of shares by a shareholder. It details the number of shares pledged, the proportion of total shares, the pledge period, and the pledgee. It also includes cumulative pledge information for related shareholders. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about shareholder share pledges, which fits the category of a Major Shareholding Notification or related shareholder transaction. Since it specifically concerns share pledging by shareholders, it aligns best with the category Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or financial data.
2021-06-29 Chinese
关于BPI-23314药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the acceptance of a clinical trial application for a drug (BPI-23314) by the National Medical Products Administration (NMPA) in China. It details the clinical trial application status, drug development progress, and potential impact on the company. The document is short (1320 characters) and serves as an official announcement of a regulatory event related to drug development, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance information. It is not a report itself but an announcement of a regulatory acceptance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-29 Chinese
股东股份减持的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the progress of shareholding reduction by specific shareholders (YINXIANG WANG and FENLAI TAN) of the company 贝达药业股份有限公司. It details the number of shares reduced, the methods of reduction, the periods, prices, and the shareholders' holdings before and after the reduction. It references compliance with relevant regulations on shareholding reduction by shareholders and senior management. There is no financial report, earnings data, or management discussion. The document is a notification about transactions in the company's own shares by insiders or major shareholders. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is 1953 characters, which is consistent with an announcement rather than a full report. Hence, the classification is POS with high confidence.
2021-06-18 Chinese
关于BPI-16350获得药品联用临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a clinical trial for a drug (BPI-16350) by the National Medical Products Administration (国家药品监督管理局). It details the clinical trial approval notice, drug information, and potential impact on the company. The document is relatively short (1572 characters) and is an announcement of regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it does not mention the release of a report but rather a regulatory approval notice. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.